RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

NCT03699956 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped RRx-001 will be studied under a new global, phase 3 clinical trial

Conditions

Carcinoma, Small Cell Lung

Interventions

COMBINATION_PRODUCT: RRx-001 + eLOOP Device
DRUG: Cisplatin/carboplatin plus etoposide

Sponsor

EpicentRx, Inc.